TRIAL DETAIL

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Drug:
Trial Name:
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Terminated
Phase:
2
Start Date 12/01/2005
Age of Trial (yrs) 19
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + Bcl-2 inhibitor
Strategy:
Block KIT + Unblock cell death genes
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CDR0000383199, MDA-2003-0761, NCI-6122
Sponsor:
MD Anderson, NCI
Patient Contact:
Jonathan Trent, MD
Contact email:
jtrent@mdanderson.org
Contact Phone:
(713) 792-3626
Randomized:
IV or Oral:
Oral Intravenous
Trial Notes:
This phase 2 trial is no longer recruiting. It combined Gleevec (imatinib) with oblimersen (a.k.a. Genasense or G3139). Oblimersen reduces the production on the Bcl-2 protein using a technology known as Antisense.
Bcl-2 is a protein involved in preventing cell death. By blocking Bcl-2 it is hoped that more tumor cells might be killed compared to Gleevec alone.

Trial Links

Trial Results

Drug Information
http://www.genta.com/genasense/
 

Trial Sites

Name
Address
City
State
Zip
Country
1505 Holcombe Blvd.
Houston
TX
77030
USA